Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 5,102 Shares of Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell sold 5,102 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $1.97, for a total value of $10,050.94. Following the transaction, the chief executive officer owned 657,737 shares of the company’s stock, valued at $1,295,741.89. This trade represents a 0.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Daniel Joseph Oconnell also recently made the following trade(s):

• On Wednesday, January 7th, Daniel Joseph Oconnell sold 37,755 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.99, for a total value of $75,132.45.
• On Monday, January 5th, Daniel Joseph Oconnell sold 4,649 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.97, for a total value of $9,158.53.

Acumen Pharmaceuticals Trading Up 1.5%

Acumen Pharmaceuticals stock traded up $0.03 during mid-day trading on Wednesday, hitting $1.99. The company’s stock had a trading volume of 220,171 shares, compared to its average volume of 159,170. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. The company has a 50 day moving average of $1.96 and a 200-day moving average of $1.67. Acumen Pharmaceuticals, Inc. has a one year low of $0.86 and a one year high of $2.46. The stock has a market cap of $120.53 million, a PE ratio of -0.90 and a beta of 0.23.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its earnings results on Wednesday, November 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.19. On average, research analysts anticipate that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ABOS. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Acumen Pharmaceuticals during the third quarter worth about $27,000. Susquehanna International Group LLP lifted its stake in Acumen Pharmaceuticals by 26.5% during the 3rd quarter. Susquehanna International Group LLP now owns 214,440 shares of the company’s stock valued at $367,000 after acquiring an additional 44,902 shares during the period. Bank of America Corp DE increased its stake in shares of Acumen Pharmaceuticals by 45.4% in the third quarter. Bank of America Corp DE now owns 213,729 shares of the company’s stock worth $365,000 after acquiring an additional 66,720 shares during the period. Bridgeway Capital Management LLC raised its holdings in shares of Acumen Pharmaceuticals by 65.1% during the third quarter. Bridgeway Capital Management LLC now owns 190,171 shares of the company’s stock worth $325,000 after purchasing an additional 75,000 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Acumen Pharmaceuticals during the third quarter valued at $691,000. Hedge funds and other institutional investors own 71.01% of the company’s stock.

Acumen Pharmaceuticals News Roundup

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Neutral Sentiment: No stated reason in filings — The disclosures show routine Form 4 sales but do not explain whether trades were pre‑planned or for personal liquidity/diversification; that ambiguity leaves market interpretation open.
• Negative Sentiment: CEO Daniel Joseph O’Connell sold a total of 47,506 shares across Jan. 5–7 (individual trades of 4,649; 5,102; and 37,755 shares), receiving about $94.3k in proceeds; the largest single trade (37,755 shares) was reported as a 5.74% reduction in his stake. Read More.
• Negative Sentiment: CFO Matt Zuga sold 14,905 shares over Jan. 5–7 (4,000; 5,100; 5,805), totaling roughly $29.4k in proceeds and small single‑trade ownership reductions (1.73%–2.61%). Read More.
• Negative Sentiment: COO Russell Barton sold 9,318 shares over Jan. 5–7 (4,000; 3,618; 1,700), raising about $18.4k and reducing his stake by small single‑trade percentages (1.32%–2.94%). Read More.
• Negative Sentiment: Insider Eric Siemers sold 10,834 shares on Jan. 5–6 (4,000; 6,834), for about $21.3k in proceeds and reported ownership reductions of ~2.35%–4.11% per trade. Read More.

Analyst Upgrades and Downgrades

ABOS has been the subject of a number of research analyst reports. Bank of America decreased their target price on Acumen Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Wall Street Zen raised shares of Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research report on Tuesday, October 14th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.75.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.